Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
March 23, 2011 | Controller & CAO | Form 4 | Conversion of derivative security | 3,333 | $2.40 | 11,073 | |
March 17, 2009 | Chief Financial Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.40 | 35,000 | |
August 15, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,750 | $2.41 | 12,250 | |
January 3, 2007 | President, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 430,000 | $2.42 | 430,000 | |
January 3, 2007 | President, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | $2.42 | 480,000 | |
October 3, 2006 | VP of Research & Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,100 | $2.44 | 9,100 | |
February 25, 2011 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | $2.49 | 255,000 | |
February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.49 | 145,000 | |
February 25, 2011 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | $2.49 | 170,000 | |
February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.49 | 70,000 | |
February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | $2.49 | 219,911 | |
February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | $2.49 | 45,000 | |
February 25, 2011 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 180,000 | $2.49 | 845,000 | |
February 25, 2011 | CAO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 16,667 | $2.49 | 38,067 | |
February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | $2.49 | 157,009 | |
May 13, 2015 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.50 | 60,081 | |
November 13, 2014 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 4,000 | $2.50 | 23,999 | |
December 4, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 19,007 | $2.50 | 43,356 | |
November 20, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,596 | $2.50 | 14,000 | |
November 19, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 404 | $2.50 | 8,404 | |
March 17, 2009 | Director, President & CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,750 | $2.56 | 60,917 | |
November 17, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 100 | $2.60 | 113,462 | |
October 3, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 4,900 | $2.70 | 25,687 | |
October 2, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,100 | $2.70 | 20,787 | |
September 20, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.70 | 18,091 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.